Stock Events

Stock Events

Addex Therapeutics 

CHF0.04
9
+CHF0+1.04% Today

Statistics

Day High
0.04
Day Low
0.04
52W High
0.09
52W Low
0.03
Volume
22,553
Avg. Volume
213,441
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27AprExpected
Q3 2024
Q1 2025
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.03
-0.02
-0.01
0
Expected EPS
0
Actual EPS
N/A

Financials

1,746.53%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
808,000Revenue
14.11MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ADXN.SW. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes plc operates in the CNS therapeutic area, making it a direct competitor to Addex Therapeutics in developing treatments for neurological disorders.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
ACADIA Pharmaceuticals specializes in CNS disorders, including Parkinson’s disease psychosis, directly competing with Addex's focus areas.
BridgeBio Pharma
BBIO
Mkt Cap12.07B
BridgeBio Pharma targets genetic diseases and cancers, including neurological disorders, overlapping with Addex Therapeutics' research focus.
Biogen
BIIB
Mkt Cap22.63B
Biogen is a major player in neurodegenerative diseases, Alzheimer's, and multiple sclerosis, competing in the CNS space.
AMGEN
AMGN
Mkt Cap160.66B
Amgen's broad focus on innovative therapeutics includes CNS disorders, positioning it as a competitor in the neurological space.
Palatin Technologies
PTN
Mkt Cap2.45M
Palatin Technologies works on developing therapeutics for diseases with a focus on CNS, making it a competitor in the neurological treatment market.
Novartis
NVS
Mkt Cap237.61B
Novartis has a diversified portfolio that includes treatments for neurological conditions, competing with Addex in the broader CNS therapeutic area.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a wide range of therapeutic areas, including CNS disorders, making it a competitor in developing treatments for neurological conditions.

About

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot?Marie?Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Show more...
CEO
ISIN
CH0029850754

Listings

LSE
GB
0QNV.LSE
SW
CH
ADXN.SW
XNAS
US
ADXN
F
DE
APE.F

0 Comments

Share your thoughts

FAQ

What is Addex Therapeutics stock price today?▼
The current price of ADXN.SW is CHF0.04 CHF — it has increased by +1.04% in the past 24 hours. Watch Addex Therapeutics stock price performance more closely on the chart.
What is Addex Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Addex Therapeutics stocks are traded under the ticker ADXN.SW.
Is Addex Therapeutics stock price growing?▼
ADXN.SW stock has risen by +0% compared to the previous week, the month change is a -18.75% fall, over the last year Addex Therapeutics has showed a -22% decrease.
When is the next Addex Therapeutics earnings date?▼
Addex Therapeutics is going to release the next earnings report on April 27, 2026.
What is Addex Therapeutics revenue for the last year?▼
Addex Therapeutics revenue for the last year amounts to 808,000 CHF.
What is Addex Therapeutics net income for the last year?▼
ADXN.SW net income for the last year is 14.11M CHF.
When did Addex Therapeutics complete a stock split?▼
The last stock split for Addex Therapeutics was on October 23, 2023 with a ratio of 1:20.